<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026597</url>
  </required_header>
  <id_info>
    <org_study_id>R727-CL-0902</org_study_id>
    <nct_id>NCT01026597</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers</brief_title>
  <official_title>A Randomized,Double-Blind,Placebo-Controlled,Ascending,Single-Dose Study of the Safety,Tolerability and Bioeffect of Intravenously Administered REGN727 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and tolerability (how the body reacts to the drug) of REGN727
      compared with placebo (an inactive substance that contains no medicine) in healthy subjects.
      The study drug and placebo will be administered by intravenous (I.V) infusion at one clinic
      visit. There will be 14 clinic visits, which will include 4 overnight stays. Subjects will be
      monitored by the study staff for side effects and the body's response to the study drug.
      Vital signs(blood pressure, temperature, breathing and heart rate) will be checked, and blood
      and urine samples will be collected at some or all visits.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106.</measure>
    <time_frame>106 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 versus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5 versus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN727</intervention_name>
    <description>5 IV cohorts (dose 1, 2, 3, 4, and 5)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_label>cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 IV cohorts (dose 1, 2, 3, 4, and 5)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_label>cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 to 65 years of age.

          -  Weight&gt; 50 kg and &lt;95 kg inclusive

          -  For women of childbearing potential, a negative serum pregnancy test at the screening
             visit and a negative urine pregnancy test on day 1.

          -  For men and women of childbearing potential, willingness to utilize adequate
             contraception and not become pregnant (or have their partner[s] become pregnant during
             the full duration of the study.

          -  Willing, committed, and able to return for all clinic visits and complete all
             study-related procedures.

          -  Able to read, understand and willing to sign the informed consent form.

        Exclusion Criteria:

          -  Initiation of a new exercise routine or major change to a previous exercise routine
             within 4 weeks prior to screening visit.

          -  Pregnant or breast-feeding women.

          -  Significant concomitant illness or history of significant illness such as cardiac,
             renal, neurological, endocrinological, metabolic or lymphatic disease, or any other
             illness or condition that would adversely affect the subject's participation in this
             study.

          -  Hospitalization for any reason within 60 days of screening.

          -  Known history of Human Immunodeficiency Virus (HIV) antibody; and/or positive
             Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the screening
             visit.

          -  Previous exposure to any therapeutic or investigational biological agent.

          -  History of alcohol or substance abuse within previous 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Swergold, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>January 24, 2015</last_update_submitted>
  <last_update_submitted_qc>January 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

